 Home > Active Ingredient News > Blood System > J Clin Oncol: Efficacy and toxicity of Pegaspargase and Calaspargase Pegol in the treatment of childhood ALL

J Clin Oncol: Efficacy and toxicity of Pegaspargase and Calaspargase Pegol in the treatment of childhood ALL

 Last Update: 2021-08-03
 Source: Internet
 Author: User

Tags

genvoya side effects

enzyme replacement therapy

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

L- asparaginase treatment of children with acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma important part (LL); however many toxic side effects, including pancreatitis, thrombosis embolism and allergic reactions
.

Although there have been decades of application experience, the best use plan to achieve the maximum efficacy and minimum toxicity of L-asparaginase is still unclear

Childhood Lymphoma Thrombosis

The DFCI 11-001 trial evaluated the efficacy and toxicity of a new type of pegylated asparaginase formulation (Calaspargase Pegol) compared with the standard formulation of Pegaspargase
.

Newly diagnosed ALL or lymphocytic lymphoma patients aged 1-21 years were randomly divided into two groups and received intravenous pegaspartase or pegylated asparaginase (2500 IU/m2)
.

After receiving an induction dose, the patient received pegaspase (1 time/2 weeks, total 15 doses) or pegylated asparaginase (1 time/3 weeks, total 10 doses) from the 7th week

Changes in median SAA levels after a single dose

From 2012 to 2015, a total of 239 patients (including 230 ALL and 9 lymphocytic lymphomas) were recruited: 120 were assigned to the pegaspase group and 119 were assigned to pegylated asparagine Enzyme group
.

After 18 days of induction therapy, 95% or more of the patients in both groups had SAA levels of 0.

Survival prognosis

With a median follow-up of 5.
3 years, the 5-year event-free survival rates of the pegaspase group and pegylated asparaginase group were 84.
9% and 88.
1%, respectively (p=0.
65)
.

With a median follow-up of 5.
3 years, the 5-year event-free survival rates of the pegaspase group and pegylated asparaginase group were 84.
9% and 88.
1%, respectively

Compared with pegasparaginase used every 2 weeks, the lowest SAA, toxicity, and survival prognosis results of pegylated asparaginase used every 3 weeks were similar
.

The SAA of the two preparations reached a high nadir, indicating that the drug delivery strategy can be further optimized

Original source:

Lynda M.

Efficacy and Toxicity of Pegaspargase and Calaspargase Pegol in Childhood Acute Lymphoblastic Leukemia: Results of DFCI 11-001 in this message

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.